Literature DB >> 8921762

Hypothenar hammer syndrome successfully managed with intravenous prostaglandin E1 and heparin and with correction of the thrombogenic risk profile. A case report.

I Wieczorek1, A Farber, K Alexander.   

Abstract

A fifty-one-year-old man presented with a history, symptoms, and clinical findings typical of a hypothenar hammer syndrome in his dominant hand. A thrombotic obstruction in the distal section of the ulnar artery with multiple downstream occlusions of proper digital arteries were documented angiographically. Coexistence of additional cardiovascular risk factors (smoking-induced polycythemia, obesity, hypercholesterolemia, and hypertension) was identified. Conservative management with intravenous heparin and prostaglandin E1 together with measures directed at controlling the additional risk factors (repeated venesection, immediate smoking cessation, and low-lipid diet) resulted in a striking clinical and angiographic improvement of the digital perfusion, without resort to interventional measures or thrombolysis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8921762     DOI: 10.1177/000331979604701113

Source DB:  PubMed          Journal:  Angiology        ISSN: 0003-3197            Impact factor:   3.619


  4 in total

1.  ["Progressive" hypothenar hammer syndrome Indication for operative treatment].

Authors:  D Klitscher; L P Müller; L Rudig; N Simiantonaki; G Arnold; P M Rommens
Journal:  Chirurg       Date:  2005-12       Impact factor: 0.955

2.  Management of Hypothenar Hammer Syndrome A Case Report.

Authors:  Brenen P Swofford; Devon P Swofford
Journal:  Am J Case Rep       Date:  2018-02-09

3.  Therapeutic management of hypothenar hammer syndrome causing ulnar nerve entrapment.

Authors:  Emanuele Cigna; Anna Maria Spagnoli; Mauro Tarallo; Liliana De Santo; Giampaolo Monacelli; Nicolò Scuderi
Journal:  Plast Surg Int       Date:  2010-06-07

4.  Combined Thenar and Hypothenar Hammer Syndromes and Raynaud's Phenomenon Successfully Treated with Iloprost.

Authors:  Alessandro Ciapetti; Marina Carotti; Marco Di Carlo; Fausto Salaffi
Journal:  Case Rep Rheumatol       Date:  2016-03-22
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.